SME
IPO ·
BSE SME
Goldline Pharmaceutical Ltd
Listed
Goldline Pharmaceuticals is engaged in the business of marketing pharmaceutical products under the brand name “Goldline.” Its product range is divided into five segments: Goldline Pharma: This category includes 42 prod
Issue details
Price band
₹41 – ₹43
Face value
₹10
Lot size
3,000 shares
Minimum investment
₹2,58,000
Issue size
₹11.61 Cr
Fresh issue
₹11.02 Cr
Offer for sale
—
Issue type
Book Built
Exchange
BSE SME
Key dates
Opens
12 May 2026
Closes
14 May 2026
UPI mandate cut-off
5:00 PM on 14 May 2026
Allotment
15 May 2026
Refunds
18 May 2026
Shares in demat
18 May 2026
Listing
19 May 2026
Subscription and listing
Subscription
598.69x
Listing price
₹59.75
Registrar
Bigshare Services Pvt Ltd
Lead manager
Cumulative Capital
Subscription by category
Total
598.69x
Total applications
1,65,088
Anchor investors
Amount raised
₹3.15 Cr
Bid date
11 May 2026
50% lock-in ends
14 Jun 2026
Rest lock-in ends
13 Aug 2026
Listing day
Issue price
₹43
Open
₹59.75
High
₹60.00
Low
₹56.77
Day close
₹56.77
Listing gain at open
+38.95%
Issue structure
Shares reserved per category and share of the total issue
QIB Shares Offered
12,72,000
47.11%
Anchor Investor Shares Offered
7,32,000
27.11%
QIB (Ex. Anchor) Shares Offered
5,40,000
20.00%
NII Shares Offered
3,90,000
14.44%
bNII > ₹10L
2,58,000
9.56%
sNII < ₹10L
1,32,000
4.89%
Retail Shares Offered
9,00,000
33.33%
Market Maker Shares Offered
1,38,000
5.11%
Total Shares Offered
27,00,000
100.00%
Finaccle’s quick read
Apply
FY25 income up 19%, PAT up 56%, ROE 21.02%, D/E 1.07, post-issue P/E 13.93x.
A rules-based screen of growth, margins, debt and valuation, built from the offer document and data on Chittorgarh.com. It is for information only and is not investment advice or a recommendation to buy or sell. Read the RHP and speak to a SEBI-registered adviser before you apply.
About the company
Goldline Pharmaceuticals is engaged in the business of marketing pharmaceutical products under the brand name “Goldline.” Its product range is divided into five segments: Goldline Pharma: This category includes 42 products to cater to specialties like Physicians, Orthopedics, ENT, Chest Physicians, General and Specialty Surgery, Gastroenterology, Neurology, and Urology. Goldline Cardinal: This category offers 54 products tailored for the Specialty division, serving medical fields such as Physicians, Diabetologists, Endocrinologists, Cardiologists, and General Physicians.
Promoters
Promoter holding
Financial performance
Period
PAT
ROE
21.02%
ROCE
24.22%
Debt / equity
1.07
PAT margin
10.38%
P/E post issue
13.93
Market cap
₹41.28 Cr
Use of IPO money
Prepayment or repayment of all or a portion of certain outstanding borrowings availed by Company
₹8.35 Cr
General Corporate Purposes
₹1.71 Cr
Issue Expense
₹1.55 Cr
Strengths
✓
Revenue up 19% in FY25 to ₹28.06 Cr
✓
PAT up 56% in FY25 to ₹2.83 Cr
✓
PAT margin of 10.38%
✓
ROE of 21.02% and ROCE of 24.22%
Risks to watch
!
SME platform: large lot size and thinner trading liquidity
!
Debt to equity of 1.07
Planning to take your own company public?
Every listing on this page started with a growing business that got its numbers, governance and paperwork ready for investors. If you are a promoter weighing an SME or main board IPO, we can tell you where you stand and what it will take.
Talk to our IPO Advisory team for readiness planning, or our IPO Consultancy team to run the listing end to end.
Last updated:
Information is compiled from exchange notices and the company’s offer document. It is for general information only and is not investment advice or a recommendation to apply. Read the prospectus before investing.